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Background: Bacterial unsaturated glucuronyl 
hydrolase (UGL) is essential for complete 
degradation of host glycosaminoglycans. 
Results: Crystal structure of Pedobacter 
heparinus UGL, Phep_2830 specific for heparin 
degradation, was determined. 
Conclusion: The pocket-like structure and lid 
loop of Phep_2830 are involved in heparin 
disaccharide recognition. 
Significance: This work contributes to 
understanding of bacterial degradation of host 
extracellular matrix components. 
 
ABSTRACT  
Extracellular matrix molecules such as 
glycosaminoglycans (GAGs) are typical 
targets for some pathogenic bacteria, which 
allow adherence to host cells. Bacterial 
polysaccharide lyases depolymerize GAGs in 
β-elimination reactions, and the resulting 
unsaturated disaccharides are subsequently 
degraded to constituent monosaccharides by 
unsaturated glucuronyl hydrolases (UGLs). 
UGL substrates are classified as 1,3- and 
1,4-types based on the glycoside bonds. 
Unsaturated chondroitin and heparin 
disaccharides are typical members of 1,3- and 
1,4-types, respectively. Here we show the 
reaction modes of bacterial UGLs with 
unsaturated heparin disaccharides by X-ray 
crystallography, docking simulation, and 
site-directed mutagenesis. Although 
streptococcal and bacillus UGLs were active 
on unsaturated heparin disaccharides, those 
preferred 1,3- rather than 1,4-type substrates. 
The genome of GAG-degrading Pedobacter 
heparinus encodes 13 UGLs. Of these, 
Phep_2830 is known to be specific for 
unsaturated heparin disaccharides. The 
crystal structure of Phep_2830 was 
determined at 1.35 Å resolution. In 
comparison with structures of streptococcal 
and bacillus UGLs, a pocket-like structure 
and lid loop at subsite +1 are characteristic of 
Phep_2830. Docking simulations of 
Phep_2830 with unsaturated heparin 
disaccharides demonstrated that the direction 
of substrate pyranose rings differs from that 
in unsaturated chondroitin disaccharides. 
Acetyl groups of unsaturated heparin 
disaccharides are well accommodated in the 
pocket at subsite +1, and aromatic residues of 
the lid loop are required for stacking 
interactions with substrates. Thus, 
site-directed mutations of the pocket and lid 
loop led to significantly reduced enzyme 
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activity, suggesting that the pocket-like 
structure and lid loop are involved in the 
recognition of 1,4-type substrates by UGLs. 
 
Glycosaminoglycan (GAG) is a 
heteropolysaccharide comprising uronic acid 
and amino sugar residues (1). Based on the 
sugar composition and mode of glycosidic 
bonds (i.e., 1,3- and 1,4-types), GAGs are 
categorized as hyaluronan, chondroitin sulfate, 
dermatan sulfate, heparan sulfate, and heparin 
(Fig. 1A, B). The polysaccharide chondroitin 
sulfate has repeating disaccharide units 
comprising β-D-glucuronic acid (GlcUA) and 
N-acetyl-D-galactosamine (GalNAc), which are 
linked via 1,3-glycosidic bonds. In contrast, 
heparin and heparan sulfate have only 1,4-type 
glycosidic bonds, which comprise repeating 
disaccharide units with uronic acid residues 
[α-L-iduronic acid (IdoUA) or β-GlcUA] and 
amino sugar residues [D-glucosamine (GlcN) or 
N-acetyl-D-glucosamine (GlcNAc)]. Constituent 
sugar residues of chondroitin sulfate and heparin 
have varying numbers of sulfate groups (2). 
With the exception of hyaluronan, these GAGs 
are present as core protein bound proteoglycans 
and play multiple roles in the architecture of 
extracellular matrices and cell growth and 
differentiation (3).  
Adhesion of microbes to eukaryotic cells 
may be a primary mechanism for residence of 
normal flora and pathogenic infections. GAGs 
are typical microbial targets for interactions with 
host cells, and some specific interactions 
between microbes and these polysaccharides 
have been described (4,5). Such microbes 
include GAG-degrading bacteria. GAGs are 
depolymerized by a variety of bacterial 
polysaccharide lyases. Based on primary 
structures, these enzymes are categorized into 
several families (PL-1–22) in the 
Carbohydrate-Active enZymes (CAZy) database 
(6-10). GAG-degrading enzymes include 
hyaluronate and chondroitin ABC lyases (family 
PL-8), and heparinase I (PL-13), -II (PL-21), 
and -III (PL-12), which have differing sequence 
and substrate specificities (9,10). Polysaccharide 
lyases depolymerize GAGs through 
β-elimination reactions and generally produce 
unsaturated disaccharides containing 
unsaturated uronic acid with C–C double bonds 
at nonreducing termini (Fig. 1B) (11). Carbon 
atoms C-3, C-4, C-5, and C-6 of unsaturated 
GlcUA (ΔGlcUA) and IdoUA (ΔIdoUA) are 
located in a single plane because of the 
formation of double bonds between C-4 and C-5 
(12). Because GlcUA is a C-5 epimer of IdoUA, 
ΔGlcUA and ΔIdoUA are identical in structure. 
Hence, both ΔGlcUA and ΔIdoUA are referred 
to as ΔGlcUA in this paper. 
Unsaturated GAG disaccharides are 
degraded to monosaccharides by unsaturated 
glucuronyl hydrolase (UGL), which is classified 
as a member of the glycoside hydrolase family 
88 in the CAZy database (Fig. 1B) (7,13). In 
contrast to other hydrolases, UGL recognizes a 
double bond in ΔGlcUA and triggers the 
hydration of C-5 (14,15). Because ΔGlcUA is a 
component of all unsaturated GAG 
oligosaccharides, UGLs are essential for the 
complete degradation of GAGs. To date, all 
bacterial UGLs are classified as members of the 
GH-88 family. However, different substrate 
specificities accommodate structural diversities 
of unsaturated GAG oligosaccharides with 
different sugar residues, glycosidic bonds, and 
degrees of sulfation. For example, streptococcal 
UGLs and Bacillus sp. GL1 enzymes 
(BacillusUGL) prefer sulfated and unsulfated 
unsaturated disaccharides with 1,3-glycosidic 
bonds, respectively (16,17). In contrast, 
Phep_2830, the UGL of Pedobacter heparinus 
(formerly known as Flavobacterium heparinum) 
degrades only unsaturated heparin disaccharides 
with 1,4-glycosidic bonds (18).  
Recent studies have focused on the 
physiological functions and structures of UGLs 
and have revealed peculiar mechanisms of UGL 
catalysis using artificial substrates (15) and that 
UGL gene disruption leads to reduced upper 
respiratory tract colonization by Streptococcus 
pneumoniae (19). Specific inhibitors of UGL are 
therefore expected to provide anti-bacterial 
drugs with no side effects. In addition, we 
demonstrated inducible mRNA expression of the 
streptococcal enzyme in the presence of GAG 
(16) and identified structural determinants of the 
preference of streptococcal UGL for sulfated 
substrates with 1,3-glycosidic bonds (12). 
However, the enzyme recognition mechanism 
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for 1,4-glycosidic bond-type substrates from 
heparin and heparan sulfate remains unknown. 
Degradation of heparins and heparan sulfates 
with 1,4-glycosidic bonds is also considered 
important for bacterial adherence and invasion 
to host cells because heparin, heparan sulfate, 
hyaluronan, and chondroitin sulfate are 
constituents of mammalian extracellular 
matrices (20). In this study, we examined the 
crystal structure of a P. heparinus UGL that has 
specific activity for unsaturated disaccharides 
with 1,4-glycosidic bonds and demonstrated the 
binding modes of these substrates with bacterial 
UGLs by X-ray crystallography, docking 
simulations, site-directed mutagenesis, and 
measurements of mutant enzyme kinetics.  
 
Experimental procedures 
Materials- Unsaturated chondroitin 
disaccharides were purchased from Seikagaku 
Biobusiness (Tokyo, Japan). Unsaturated 
heparin disaccharides were purchased from 
Iduron (Manchester, UK) and Sigma-Aldrich (St. 
Louis, MO, USA). Restriction endonucleases 
and DNA-modifying enzymes were purchased 
from Toyobo (Osaka, Japan). All other analytical 
grade chemicals were obtained from commercial 
sources.  
Overexpression- Overexpression systems 
for P. heparinus UGLs (Phep_2238, Phep_2649, 
and Phep_2830) were constructed in 
Escherichia coli cells as follows. Three P. 
heparinus UGL genes were amplified from the 
genome of P. heparinus by polymerase chain 
reaction (PCR). PCR was performed using P. 
heparinus genomic DNA as a template, 
synthetic oligonucleotide primers, and 
KOD-FX-neo polymerase (Toyobo). Forward 













TC-3′. Restriction sites for NdeI and XhoI are 
shown as underlined 5′ regions. The PCR 
conditions were as follows: 94°C for 2 min 
followed by 30 cycles of 98°C for 10 s, 55°C for 
30 s, and 68°C for 30 s. PCR products were 
ligated with HincII-digested pUC119 (Takara, 
Shiga, Japan) using Ligation High Ver. 2 
(Toyobo) in accordance with the manufacturer’s 
protocol, and the resulting plasmids were 
digested with NdeI and XhoI to isolate UGL 
gene fragments. Phep_2238 and Phep_2649 
DNA fragments were ligated with NdeI- and 
XhoI-digested pET21b vectors (Novagen, 
Darmstadt, Germany), and the Phep_2830 DNA 
fragment was ligated into NdeI- and 
XhoI-digested pCold IV vector (Takara Bio, 
Shiga, Japan) using Ligation High Ver. 2. The 
resulting plasmids were designated 
pET21b-Phep_2238, pET21b-Phep_2649, and 
pCold IV-Phep_2830, respectively. To 
overexpress Phep_2238, Phep_2649, and 
Phep_2830, E. coli BL21(DE3) host cells 
(Novagen) were transformed with 
pET21b-Phep_2238 and pET21b-Phep_2649, 
and E. coli Rosetta-gami B host cells (Novagen) 
were transformed with pCold IV-Phep_2830.  
Microorganisms and culture conditions- To 
express Phep_2238 or Phep_2649, E. coli 
BL21(DE3) cells harboring pET21b-Phep_2238 
or pET21b-Phep_2649 plasmids were cultured 
at 37°C in Luria broth (Sigma-Aldrich) 
supplemented with sodium ampicillin (100 μg 
ml−1). When turbidity at 600 nm reached 0.3–0.7, 
isopropyl-β-D-thiogalactopyranoside was added 
to the culture to a final concentration of 0.1 mM, 
and the cells were further cultured at 16°C for 
44 h. To overexpress Phep_2830, E. coli 
Rosetta-gami B cells harboring pCold 
IV-Phep_2830 were cultured at 37°C in Luria 
broth supplemented with sodium ampicillin (100 
μg ml−1) and chloramphenicol (33 μg ml−1). 
When turbidity at 600 nm reached 1–1.2, the 
cells were cooled to 15°C with ice water, 
isopropyl-β-D-thiogalactopyranoside was added 
to the culture to a final concentration of 0.4 mM, 
and the cells were further cultured at 15°C for 
44 h. 
Purification- Purification of S. agalactiae 
UGL (SagUGL), S. pneumoniae UGL 
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(SpnUGL), S. pyogenes UGL (SpyUGL), 
SagUGL mutant S368G (12)], and BacillusUGL 
were expressed and purified as described 
previously (12,16,21). E. coli cells harboring 
pET21b-Phep_2238, pET21b-Phep_2649, or 
pCold IV-Phep_2830 plasmids were collected 
by centrifugation at 6700 ×g for 10 min at 4°C. 
Cells harboring pET21b-Phep_2238 or 
pET21b-Phep_2649 were resuspended in 20 
mM potassium phosphate buffer (KPB, pH 6.0), 
and the cells harboring pCold IV-Phep_2830 
were resuspended in a solution containing 20 
mM tris (hydroxymethyl) 
aminomethane–hydrochloric acid (Tris–HCl; pH 
7.5), 1 mM dithiothreitol, and 1 mM 
ethylenediaminetetraacetic acid. Cells were 
ultrasonically disrupted (Insonator model 201M; 
Kubota, Osaka, Japan) at 9 kHz for 10 min at 
0°C, and the supernatant obtained by 
centrifugation at 28,000 ×g for 20 min at 4°C 
was used as a cell extract. Phep_2238 and 
Phep_2649 were purified by cation exchange 
chromatography (TOYOPEARL CM-650, 
Tosoh, Tokyo, Japan) followed by gel filtration 
chromatography (HiLoad 16/60 Superdex 75 pg, 
GE Healthcare, Little Chalfont, UK). 
Phep_2830 was purified by anion exchange 
chromatography (HiLoad 16/10 Q Sepharose, 
GE Healthcare) followed by gel filtration 
chromatography (HiLoad 16/60 Superdex 75 
pg). Purity was assessed using sodium dodecyl 
sulfate–polyacrylamide gel electrophoresis (22). 
Enzyme assay- Reactions of SagUGL, 
SpnUGL, SpyUGL, and BacillusUGL were 
conducted at 30°C in 500 μl solutions of 20 mM 
Tris–HCl (pH 7.5), 0.2 mM substrate, and 
enzyme. Reactions of Phep_2238, Phep_2649, 
and Phep_2830 were conducted at 30°C in 500 
μl solutions containing 100 mM KPB (pH 6.0), 
0.2 mM substrate, and enzyme. Concentrations 
and pH of each buffer were adopted in 
accordance with previous reports (12,18). 
Enzyme activity was measured by monitoring 
decreases in absorbance at 235 nm, which 
corresponded to the loss of substrate C–C 
double bonds.  
Unsaturated chondroitin disaccharides were 
used as substrates, and their molar absorption 
coefficients at 235 nm [ε235 (M−1 cm−1)] were as 
follows: ΔGlcUA-1,3-GalNAc (CΔ0S), ε235 = 
4800; ΔGlcUA-1,3-GalNAc with a sulfate group 
at the C-4 position of GalNAc (CΔ4S), ε235 = 
4800; and ΔGlcUA-1,3-GalNAc with a sulfate 
group at the C-6 position of GalNAc (CΔ6S), 
ε235 = 4800 (12). Unsaturated heparin 
disaccharides were also used as substrates, and 
their molar absorption coefficients at 235 nm 
were as follows: ΔGlcUA-1,4-GlcNAc 
(HΔNAc0S), ε235 = 4524; ΔGlcUA-1,4-GlcN 
with a sulfate group at the N position of GlcN 
(HΔNS), ε235 = 6600; ΔGlcUA-1,4-GlcN with a 
sulfate group at the C-6 position of GlcN 
(HΔ6S), ε235 = 4826; ΔGlcUA-1,4-GlcNAc with 
a sulfate group at the C-6 position of GlcNAc 
(HΔNAc6S), ε235 = 4300; ΔGlcUA-1,4-GlcN 
with sulfate groups at N and C-6 positions of 
GlcN (HΔNS6S), ε235 = 6075; 
ΔGlcUA-1,4-GlcN with sulfate groups at the 
C-2 position of ΔGlcUA and the N position of 
GlcN (HΔ2’SNS), ε235 = 4433 (18).  
Kinetic parameters of SagUGLs (wild-type, 
S365A, S365G, S368A, S368G, and K370A), 
BacillusUGL, Phep_2238, Phep_2649, and 
Phep_2830s (wild-type and F164A) with 
various unsaturated GAG disaccharides were 
determined using assays of UGL activity at 
30°C, in which decreases in substrate 
absorbance at 235 nm were monitored. Reaction 
mixtures of SagUGLs and BacillusUGL 
contained substrate, 20 mM Tris–HCl (pH 7.5), 
and enzyme. Reaction mixtures for Phep_2238, 
Phep_2649, and Phep_2830s contained substrate, 
100 mM KPB (pH 6.0), and enzyme. Substrate 
concentrations ranges were fixed at 0.05–1.0 
mM because the absorbance at 235 nm of the 
substrate at over 1.0 mM exceeds measurement 
limitations on the spectrometer. 
Michaelis–Menten constants (Km) and turnover 
numbers (kcat) were calculated by fitting the data 
using the KaleidaGraph software (Synergy 
Software, Reading, PA, USA). 
Docking simulations- To perform docking 
analyses of UGLs and substrates, our 
coordinates of SagUGL were used from the 
Protein Data Bank (PDB, http://www.rcsb.org). 
The structure of ligand-free SagUGL (PDB ID: 
2ZZR) was selected as a receptor model. 
Docking analyses were performed using the 
AutoDock 4.2 program (23). The coordinates of 
CΔ6S were obtained from coordinates of 
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SagUGL complexed with CΔ6S (PDB ID: 
3ANK), and coordinates of unsaturated heparin 
disaccharides were obtained using 
ACD/ChemSketch Freeware, version 5.12 
(Advanced Chemistry Development, Inc., 
Toronto, ON, Canada) and the OpenBabel 
program (24). Asp-175 and Lys-370 of SagUGL 
were treated as flexible residues because 
Asp-175 of SagUGL was critical for catalysis 
and Lys-370 showed movement during 
interactions with CΔ6S (12,16). The number of 
genetic algorithm runs was set to 20. Figures for 
protein structures and docking forms were 
prepared using the Pymol program (25). 
Site-directed mutagenesis- Three residues 
(Ser-365, Ser-368, and Lys-370) of SagUGL 
were substituted with Ala or Gly, Ala, and Ala, 
and the resulting mutants were designated 
S365A, S368A, S368A, and K370A, 
respectively. Asp-182 of Phep_2238, and Arg-57, 
Phe-164, Asp-174, and Gly-362 of Phep_2830 
were also substituted with Asn, Ala, Ala, Asn, 
and Tyr, and the resulting mutants were 
designated D182N, R57A, F164A, D174N, and 
G362Y, respectively. With the exception of 
D174N and G362Y, UGL mutants were 
constructed using a Quik Change site-directed 
mutagenesis kit (Agilent Technologies, Santa 
Clara, CA, USA). D174N and G362Y were 
constructed using a KOD-Plus Mutagenesis Kit 
(Toyobo) in accordance with the manufacturer’s 
protocol. The plasmids pET21b-SagUGL and 
pCold IV-Phep_2830 were used as PCR 
templates for SagUGL and Phep_2830, 
respectively, and synthetic oligonucleotides 
were used as sense and antisense primers. Sense 
and antisense primers sequences were as follows 




































TGGTTCTCGCCG-3’. PCR was performed 
using KOD-Plus-Neo polymerase (Toyobo). 
Mutations were confirmed using the 
dideoxy-chain termination method with the 
automated DNA sequencer model 3730xl 
(Applied Biosystems, Foster City, CA, USA) 
(26). E. coli HMS174 (DE3) host cells 
(Novagen) were transformed with SagUGL 
mutant plasmids. Expression and purification of 
SagUGL mutants were conducted using the 
procedure for wild-type SagUGL as described 
previously (12). Phep_2830 mutant plasmids 
were digested with NdeI and XhoI, and the 
resulting DNA fragments were ligated with NdeI 
and XhoI-digested pCold II vector (Takara Bio) 
to express Phep_2830 mutant proteins with 
N-terminal histidine tags for purification. 
N-terminal histidine tagged Phep_2830 
reportedly exhibits comparable enzyme activity 
to that of the histidine tag-free enzyme (18). The 
Phep_2830 mutants R57A, F164A, and G362Y 
were purified to almost homogeneity by affinity 
chromatography (TALON, Clontech, Mountain 
View, CA, USA).  
X-ray crystallography- To determine the 
three-dimensional structure of Phep_2830, the 
purified enzyme was crystallized using sitting drop 
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vapor diffusion. Solutions containing 1 μl proteins 
(10 mg ml−1) in 20 mM Tris–HCl (pH 7.5), 1 mM 
dithiothreitol, and 1 mM 
ethylenediaminetetraacetic acid were mixed 
with equal volumes of reservoir solution 
containing 25% polyethylene glycol 6000, 0.1 
M 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES; pH 7.5), and 0.1 M lithium 
chloride. Protein solutions were then incubated 
at 20°C, and single crystals were grown for 
about 2 months. The crystal was flash-cooled 
under a cold nitrogen stream. Diffraction data 
were collected at λ = 1 Å using an ADSC Q315 
detector at the BL38B1 station of SPring-8, 
Harima, Japan. The data were processed using 
the HKL2000 program (27). Molecular 
replacements for structure determinations were 
conducted using the Molrep program supplied in 
the CCP4 program package with coordinates of 
SagUGL (PDB ID: 2ZZR) as an initial model 
(28,29). Structure refinement was conducted 
with the Phenix.refine program supplied in the 
PHENIX program package (30,31). Randomly 
selected 5% reflections were excluded from 
refinement and were used to calculate Rfree. After 
each cycle of refinement, the model was 
manually adjusted using the Coot program (32). 
The final model quality was checked using the 
PROCHECK program (33). Superpositioning of 
protein models and calculation of their root 
mean square deviations (r.m.s.d.) were 
conducted using the LSQKAB program supplied 
with the CCP4 program package (34). 
 
Results and Discussion 
Enzyme activity of streptococcal UGLs 
toward unsaturated heparin disaccharides- 
Three streptococcal UGLs (SagUGL, SpnUGL, 
and SpyUGL) were purified to homogeneity, 
and their enzyme activities (U mg−1) toward a 
variety of unsaturated heparin disaccharides 
were measured (Table 1). All three streptococcal 
UGLs degraded HΔNS with greater efficiency 
than the other unsaturated heparin disaccharides. 
Kinetic parameters of SagUGL toward HΔNS 
were determined as follows: Km, 1.9 mM; kcat, 
3.9 s−1. SagUGL is known to exhibit the highest 
enzymatic activity toward CΔ6S with 
1,3-glycosidic bond (12) as follows: Km, 0.10 
mM; kcat, 10 s−1, indicating that the enzyme 
activity of SagUGL toward unsaturated heparin 
disaccharides was lower than that toward 
unsaturated chondroitin disaccharides. Indeed, 
kcat Km−1 with HΔNS was 50-fold lower than 
with CΔ6S (12). The enzyme activities of 
BacillusUGL with each unsaturated heparin 
disaccharide were also measured. BacillusUGL 
exhibited the highest enzyme activity toward 
HΔNAc0S distinct from streptococcal UGLs 
(Table 1). BacillusUGL also demonstrated 
specificity for unsulfated unsaturated 
chondroitin disaccharides (17). These results 
and our previous reports (16,17) demonstrate 
that streptococcal UGLs exhibit high enzyme 
activity toward disaccharides with specific 
sulfate groups, whereas BacillusUGL 
preferentially degrades unsulfated substrates.  
Recognition of unsaturated heparin 
disaccharides by streptococcal UGL- Structure 
determinations of SagUGL in complex with 
HΔNS were difficult, possibly due to its lower 
affinity for this disaccharide. Thus, to elucidate 
the binding modes of unsaturated heparin 
disaccharide with SagUGL, the structure of 
SagUGL in complex with HΔNS was predicted 
using the docking simulation program AutoDock. 
To evaluate the suitability of the AutoDock 
program, docking simulations were performed 
with our coordinates of ligand-free SagUGL 
(PDB ID: 2ZZR) and CΔ6S. The simulated 
complex structure with the lowest binding 
energy was almost identical to the crystal 
structure of SagUGL/CΔ6S except that Lys-370 
forms hydrogen bond with a sulfate group (PDB 
ID: 3ANK; Fig. 2A, B), indicating that the 
AutoDock docking simulation accurately 
determined the substrate-bound UGL structure. 
Thus, the binding mode of HΔNS to SagUGL 
was calculated using an AutoDock program, 
indicating the accommodation of HΔNS in the 
active site of SagUGL (Fig. 2C). The direction 
of the pyranose ring of GlcN toward ΔGlcUA of 
HΔNS opposed that of GalNAc in CΔ6S (Fig. 
1C). Due to these differences in direction, the 
amino group of GlcN in HΔNS is located at a 
similar position to the C-6 of GalNAc in CΔ6S, 
and the position of a sulfate group in HΔNS 
corresponds to that of the sulfate group in CΔ6S. 
The directions of HΔNS pyranose rings 
indicated by docking simulations were similar to 
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those of heparin in solution, which were 
determined by X-ray scattering (35). This 
docking simulation suggests that Ser-365, 
Ser-368, and Lys-370 residues of SagUGL form 
hydrogen bonds with the sulfate group of HΔNS. 
To confirm the functions of Ser-365, Ser-368, 
and Lys-370 of SagUGL, the SagUGL mutants 
S365A, S365G, S368A, S368G, and K370A 
were purified and assayed. Kinetic parameters 
of each mutant were determined and compared 
with those of wild-type SagUGL (Table 2). Km 
values of S365G, S365A, S368G, and S368A for 
HΔNS were higher than that of the wild-type 
enzyme, whereas that of K370A was lower. The 
kcat values of S365G, S368G, and in particular 
K370A for HΔNS were also decreased (kcat of 
K370A was approximately 50-fold lower than 
that of WT). This mutant analysis shows that 
Ser-365 and Ser-368 of SagUGL are involved in 
binding to HΔNS, whereas Lys-370 enhances 
the reaction efficiency of SagUGL rather than 
the binding affinity for HΔNS. In contrast, 
although the binding modes of the other 
unsaturated heparin disaccharides to SagUGL 
were calculated, no structures of 
substrate-bound SagUGL were obtained (data 
not shown). These docking simulations and 
enzyme assays of SagUGL (Table 1) suggest 
that, with the exception of HΔNS, its affinity 
toward unsaturated heparin disaccharides is also 
remarkably low.  
Docking simulations of HΔNS with 
SagUGL, site-directed mutagenesis, and kinetic 
analyses demonstrate that Ser-365 and Ser-368 
residues of SagUGL contribute to recognition of 
the sulfate group of HΔNS and that the Lys-370 
residue is involved in degradation of the 
substrate. These amino acid residues constitute 
the motif SXXSXK, which plays an important 
role in the recognition of the sulfate group of 
CΔ6S (12). Streptococcal UGLs acted on 
unsaturated heparin disaccharides, although 
their enzyme activities toward these substrates 
were low. In addition, putative heparan sulfate 
lyase is encoded in the vicinity of the 
streptococcal UGL gene, suggesting that 
streptococcal UGLs contribute to the 
degradation of heparan sulfate.  
Substrate specificity of P. heparinus UGLs- 
The structural determinants of SagUGL 
recognition of HΔNS sulfate groups were 
calculated using docking simulations. However, 
the intrinsic UGL-binding mechanism of 
substrates containing 1,4-glycosidic bonds 
remains to be clarified. Therefore, the 
mechanisms behind UGL recognition of 
unsaturated heparin disaccharides were analyzed 
using high affinity UGL interactions with 
unsaturated heparin disaccharides. One 
(Phep_2830) of the UGLs of P. heparinus, 
which assimilates heparin as a carbon source, is 
known to specifically degrade substrates 
containing 1,4-glycosidic bonds. Thirteen UGL 
genes of P. heparinus were assigned by 
complete genome sequences (36) and the three 
UGLs Phep_2238, Phep_2649, and Phep_2830 
were overexpressed in E. coli cells and were 
purified to homogeneity and assayed for activity 
(Table 1).  
Phep_2238 degraded HΔNAc0S and HΔNS 
more efficiently than other unsaturated heparin 
disaccharides. Moreover, Phep_2238 exhibited 
comparably lower enzyme activity toward 
substrates with 1,3-glycosidic bonds, such as 
CΔ0S, CΔ4S, and CΔ6S, than those with 
1,4-glycosidic bonds. The kinetic parameters Km 
and kcat of Phep_2238 toward HΔNS were 0.073 
mM and 2.3 s−1, respectively. Phep_2649 
preferred CΔ6S but also degraded CΔ0S, 
HΔNAc0S, and HΔNS, although its specific 
activity was lower than that of the streptococcal 
UGLs, BacillusUGL, Phep_2238, and 
Phep_2830. Km and kcat values of Phep_2649 
toward HΔNS were 0.052 mM and 0.17 s−1, 
respectively. Although a UGL that degrades 
unsaturated chondroitin disaccharide (CΔ6S) 
was previously isolated as a 1,3-glycuronidase 
from P. heparinus (37), this enzyme differs 
from Phep_2238 and Phep_2649 in amino acid 
composition, isoelectric point, and molecular 
weight. In contrast, Phep_2830 exhibited 
enzyme activity toward only unsaturated 
heparin disaccharides, as described previously 
(18). Km and kcat values of Phep_2830 toward 
HΔNAc6S were 0.029 mM and 16 s−1, 
respectively. 
Crystal structure of Phep_2830- Because 
Phep_2238 and Phep_2830 showed high 
enzyme activity toward various unsaturated 
heparin disaccharides, these enzymes were 
Complete bacterial degradation of heparin 
8 
 
crystallized to clarify the mechanisms by which 
UGL recognizes substrates with 1,4-glycosidic 
bonds based on tertiary structures. Phep_2830 
was successfully crystallized, and X-ray 
diffraction data were collected. The crystal 
structure of Phep_2830 was determined at a 
resolution of 1.35 Å using molecular 
replacement with the SagUGL structure (PDB 
ID: 2ZZR) as an initial model. Data collection 
and model refinement statistics are summarized 
in Table 3. The final model contains one 
monomer enzyme from Gly-28 to Thr-398, a 
molecule of HEPES, and 422 water molecules. 
The N-terminal region from Met-1 to Asn-27 
could not be assigned because the electron 
density map was too thin. Similar to SagUGL 
and BacillusUGL, the overall structure of 
Phep_2830 has a α6/α6-barrel architecture, and 
Phep_2830 contains 12 α helices and 5 β strands 
(Fig. 3A). The r.m.s.d. for all of the 336 Cα 
atoms between Phep_2830 and SagUGL was 1.7 
Å, indicating that both have a common basic 
scaffold structure. In contrast, approximately 10 
C-terminal amino acid residues of Phep_2830 
protrude forward from the outside of the protein. 
Previous studies show that Asp-149 of 
BacillusUGL and Asp-175 of SagUGL act as 
critical catalysts (14,16). Thus, to investigate the 
catalytic mechanisms of P. heparinus UGLs, 
corresponding residues of Phep_2238 (Asp-182) 
and Phep_2830 (Asp-174) were substituted with 
Asn. Both mutant enzymes were inactive, 
indicating that the catalytic mechanisms of 
Phep_2238 and Phep_2830 are similar to those 
of SagUGL and BacillusUGL.  
Active sites were structurally compared by 
superimposing coordinates of Phep_2830 on 
those of SagUGL (PDB ID: 2ZZR) and 
BacillusUGL/CΔ0S (PDB ID: 2AHG; Fig. 
3B–D). Subsites were defined such that −n 
represents the nonreducing terminus, +n 
represents the reducing terminus, and cleavage 
occurs between these sites (38). The amino acid 
residues and their positions at subsite −1, which 
is the binding site of ΔGlcUA, were common to 
all three UGLs (Fig. 3B). However, the 
structures at subsite +1, which is the binding site 
of an amino sugar, differed significantly (Fig. 
3C, D). In particular, Ser-365, Ser-368, and 
Lys-370 of SagUGL comprise the motif 
SXXSXK, which contributes to the recognition 
of a sulfate group (12). These three residues are 
not conserved in Phep_2830 and correspond to 
the Ala-363, Tyr-366, and Ser-368 residues of 
Phep_2830, respectively. These observations 
indicate that Phep_2830 recognition of substrate 
sulfate groups differs from that of SagUGL. 
Regarding hydrophobic amino acid residues 
forming a stacking interaction with an amino 
sugar at the subsite +1, the Tyr-338 residue of 
BacillusUGL (or the Tyr-364 residue of 
SagUGL), which is located around C-6 position 
of GalNAc in BacillusUGL/CΔ0S is substituted 
with the Gly-362 residue in Phep_2830, while 
the Trp-134 residue of BacillusUGL (or the 
Trp-161 residue of SagUGL) is conserved in 
Phep_2830. Due to this difference, this large 
space in Phep_2830 occurs around Gly-362, and 
is distinct from that of SagUGL and 
BacillusUGL. As described above, the Phe-164 
residue of Phep_2830 that corresponds to 
Glu-163 of SagUGL or Pro-136 of BacillusUGL 
also lies at the binding site of an amino sugar 
(Fig. 3C, D). The loop comprising amino acid 
residues 163–169 of Phep_2830, which is 
designated loop A and corresponds to residues 
162–170 of SagUGL and 135–144 of 
BacillusUGL, covers the active site. However, 
these loops of both SagUGL and BacillusUGL 
are distal from those at the active site. 
Accordingly, the Phe-164 residue of Phep_2830 
is proximal to the active site (Fig. 3D). These 
Phep_2830 specific amino acid residues may be 
involved in stacking interactions with substrates, 
especially with amino sugars. Indeed, whereas 
Arg-57, Arg-66, and Glu-369 residues of 
Phep_2830 are arranged at subsite +1, these are 
not conserved in the active sites of either 
SagUGL or BacillusUGL.  
Binding mode of unsaturated heparin 
disaccharides to Phep_2830- To clarify the 
mechanism by which Phep_2830 recognizes 
unsaturated heparin disaccharides, we attempted 
to prepare complexes of Phep_2830 with these 
substrates but failed. Thus, the binding modes of 
unsaturated heparin disaccharides (HΔNAc0S, 
HΔNS, HΔ6S, and HΔNAc6S) to Phep_2830 
were estimated in a similar way to those of 
SagUGL using the AutoDock program. In these 
simulations, structures of Phep_2830-bound 
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HΔNAc0S, HΔNS, and HΔNAc6S were 
successfully calculated and that of the 
Phep_2830–HΔNAc0S complex is shown in Fig. 
2D. Two common features were observed in the 
three docking structures that exhibited low 
binding energies. Similar to the docking 
simulation of SagUGL with HΔNS, the direction 
of the pyranose ring of GlcNAc (or GlcN 
sulfated at the N position) toward ΔGlcUA was 
opposed to that of GalNAc in complex with 
SagUGL/CΔ6S and BacillusUGL/CΔ0S (Fig. 
1C). In addition, the acetyl groups of HΔNAc0S 
and HΔNAc6S (or the sulfate group of HΔNS) 
were predicted to be accommodated in the 
pocket-like structure comprising Arg-57, Arg-66, 
Trp-73, Gly-362, Ala-363, Tyr-366, Ser-368, and 
Glu-369 residues, which was designated the 
acetyl/sulfate group-binding pocket (Fig. 2D, E). 
No similar pocket-like structures were observed 
in SagUGL and BacillusUGL, which prefer 
substrates with 1,3-glycosidic bonds (Fig. 3C). 
The Trp-162 and Phe-164 residues in loop A of 
Phep_2830 (Fig. 3D) are located close to the 
C-6 position of an amino sugar of unsaturated 
heparin disaccharides. As described above, 
Trp-161, Trp-134, and Trp-162 residues of 
SagUGL, BacillusUGL, and Phep_2830, 
respectively, are situated at almost identical 
positions, whereas the residues of SagUGL and 
BacillusUGL that correspond to Phe-164 of 
Phep_2830 are distal from subsite +1.  
To confirm that this pocket-like structure 
and loop A contribute to recognition of 
unsaturated heparin disaccharides, Arg-57, 
Phe-164, and Gly-362 residues of Phep_2830 
were substituted with Ala, Ala, and Tyr, 
respectively. The resulting mutants R57A, 
F164A, and G362Y were expressed in E. coli 
with N-terminal His-tags and were purified 
using affinity columns. Although their 
expression was confirmed by SDS-PAGE (Fig. 
4), two mutants of pocket-like structure (R57A 
and G362Y) exhibited no detectable enzyme 
activity with unsaturated heparin disaccharides 
as well as unsaturated chondroitin disaccharides. 
The Km value (1.4 mM) of F164A toward 
HΔNAc6S was about 50 fold higher than that 
(0.029 mM) of the wild-type enzyme, whereas 
there was no significant difference in kcat 
between wild-type enzyme (16 s−1) and F164A 
(22 s−1). These site-directed mutagenesis 
experiments indicated that the pocket-like 
structure and loop A play a significant role in 
recognizing substrates. In contrast, the absence 
of the acetyl group may have led to low specific 
activity of Phep_2830 toward HΔ6S and 
hampered docking simulations of the complex 
of Phep_2830 with HΔ6S. Hence, substrates 
containing 1,4-glycosidic bonds are readily 
inserted into the acetyl/sulfate group-binding 
pocket of Phep_2830 through stacking 
interactions of loop A residues, Phe-164 and 
Trp-162, with an amino sugar. Simultaneously, 
Trp-162 and Phe-164 residues may inhibit 
binding of Phep_2830 with substrates 
containing 1,3-glycosidic bonds. 
Comparisons of the active site structures 
and docking simulations suggest that the 
acetyl/sulfate group-binding pocket comprising 
Arg-57, Arg-66, Trp-73, Gly-362, Ala-363, 
Ser-368, and Glu-369, and the loop A including 
Trp-162 and Phe-164, are important for binding 
of Phep_2830 to unsaturated heparin 
disaccharides. Among these amino acid residues, 
Arg-57, Trp-73, Gly-362, Glu-369, and Trp-162 
are conserved in Phep_2238 and Phep_2649 
(Fig. 5). Moreover, Arg-66, Ala-363, Tyr-366, 
Ser-368, and Phe-164 of Phep_2830 correspond 
with Val-73, His-373, Gly-376, Ser-378, and 
Ser-171 of Phep_2238 and Arg-59, Ser-362, 
His-365, Asn-367, and Val-158 of Phep_2649, 
respectively. These differences in primary 
structure may lead to changes in pocket shapes 
but do not occupy the space. However, Ser-171 
of Phep_2238 and Val-158 of Phep_2649, which 
correspond to Phe-164 of Phep_2830, do not 
form stacking interactions because they are 
smaller than Phe. Hence, these structural 
features may enable recognition of substrates 
with 1,3-glycosidic bonds by Phep_2238 and 
Phep_2649. Although the pocket-like structure 
of Phep_2649 was arranged with high 
probability, the activity of the enzyme for 
unsaturated heparin disaccharides was lower 
than that of Phep_2238 and Phep_2830. In 
addition, the relative length of amino acid 
residues of Phep_2649 that correspond to the 
loop A may contribute to low enzyme activity. 
Bacteroides species, human intestinal 
bacteria, are known to produce family PL-12, 13, 
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and 21 heparinases depolymerizing heparin to 
unsaturated disaccharides through β-elimination 
reaction (39-43), while complete degradation of 
heparin to monosaccharides remains to be 
clarified. Four UGL-homologous proteins are 
encoded in the genomes of Bacteroides stercoris 
(BACSTE_02470, BACSTE_03202, 
BACSTE_03210, and BACSTE_03707) and 
Bacteroides thetaiotaomicron (BT_0146, 
BT_2913, BT_3348, and BT_4658). Arg-57 and 
Gly-362, key residues comprising the 
pocket-like structure of Phep_2830, are 
conserved in these bacteroides UGLs 
(Supplemental Fig. S1), suggesting that, similar 
to Phep_2238 and Phep_2830, bacteroides 
enzymes preferentially degrade unsaturated 
heparin disaccharides to constituent 
monosaccharides. Consequently, structural 
determinants of Phep_2830 for 1,4-specificity 
found in this study promotes a better 
understanding of the complete degradation of 
heparin by Bacteroides species. 
In conclusion, tertiary and active site 
structures of UGLs that are specific for 
unsaturated heparin disaccharides containing 
1,4-glycosidic bonds were determined for the 
first time. Comparisons of the active site 
structures, docking simulations, and 
site-directed mutagenesis experiments 
demonstrate the significance of the 
acetyl/sulfate group-binding pocket and the lid 
loop at subsite +1 in Phep_2830 for recognition 
of substrates with 1,4-glycosidic bonds. 
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Figure 1. Degradation of GAGs  
(A) Examples of GAGs containing 1,3-glycosidic bonds (hyaluronan) and 1,4-glycosidic bonds 
(heparan sulfate); (B) schematic of chondroitin degradation by lyase and UGL; (C) directions of 
pyranose rings of an unsaturated chondroitin disaccharide and an unsaturated heparin disaccharide 
in complex with UGLs.  
 
Figure 2. Binding mode of unsaturated disaccharides to bacterial UGLs (stereo diagram)  
(A) Our crystal structure of SagUGL in complex with CΔ6S determined by X-ray crystallography 
(PDB ID: 3ANK); (B) an active site structure of SagUGL/CΔ6S; (C) an active site structure of 
SagUGL/HΔNS; (D) an active site structure of Phep_2830/HΔNAc0S; (E) surface of the pocket 
recognizing acetyl group; (B)–(E) structures estimated via docking simulations; numbers of carbon 
atoms are shown (B) and (C). Atoms C of SagUGL, C of Phep_2830, O, N, and S are in yellow, 
purple, red, blue, and green, respectively.  
 
Figure 3. Crystal structure of Phep_2830 (stereo diagram) 
(A) Overall structure of Phep_2830. Blue, pink, and green denote the secondary structure elements 
α-helices, β-sheets, and loops, respectively; (B) amino acid residues of the three UGLs Phep_2830, 
SagUGL, and BacillusUGL/CΔ0S at subsite −1; (C) amino acid residues of the three UGLs at 
subsite +1; (D) each loop comprises amino acid residues 163–169 of Phep_2830, 162–170 of 
SagUGL, and 135–144 of BacillusUGL. Sticks indicate side chains of Trp-162 and Phe-164 of 
Phep_2830, Trp-161 of SagUGL, and Trp-134 of BacillusUGL. (B)–(D) Phep_2830, SagUGL 
(PDB ID: 2ZZR), and BacillusUGL in complex with CΔ0S (PDB ID: 2AHG) are indicated in 
purple, cyan, and yellow, respectively. Atoms O and N of CΔ0S are colored red and blue, 
respectively.  
 
Figure 4. SDS-PAGE profile 
Lane M, molecular weight standards (from top): synthetic polypeptides with molecular weights of 
250,000, 150,000, 100,000, 75,000, 50,000, 37,000, 25,000, and 20,000; lane 1, R57A; lane 2, 
F164A; lane 3, G362Y. 
 
Figure 5. Multiple sequence alignments of UGLs  
Primary structures of Phep_2238, Phep_2649, Phep_2830, SagUGL, and BacillusUGL were used 
for sequence alignments. Identical and similar amino acid residues among proteins are denoted by 
asterisks and dots, respectively. Amino acid residues of the acetyl/sulfate group-binding pocket are 
indicated in boxes. The residues corresponding to loop A are shaded. Arrows indicate positions of 
Trp-162 and Phe-164 of Phep_2830.  




Substrate specificity of bacterial UGLs  
Specific activity (U mg−1)  
  SagUGL SpnUGL SpyUGL BacillusUGL Phep_2238 Phep_2649 Phep_2830 
HΔNAc0S 0.016  0.0055 0.0033  5.3  12  0.30  15  
HΔNS 0.77  0.14  0.10  1.8  11  1.1 7.1  
HΔ6S 0.0088  0.0018  0.00094 0.081  1.2  NDa 1.9  
HΔNAc6S 0.035  0.0059 0.0066 0.016  7.9  ND 18  
HΔNS6S 0.0080  0.0031 ND 0.0050  4.2 ND 4.5 
HΔ2'SNS 0.0023  0.0024  ND 0.0095  ND ND ND 
CΔ0S 0.72  0.99 0.63 10  2.6  0.70 ND 
CΔ4S 0.0019  ND 0.0046 ND 0.31  ND ND 
CΔ6S 17  6.1 5.3  1.8  3.2  1.7  ND 
aNot detected 




Kinetic parameters of SagUGL mutants for HΔNS 
 
Km kcat kcat Km−1 
(mM) (s−1) (mM−1 s−1) 
WT 1.9 ± 0.2  3.8 ± 0.4  2.0  ± 0.3  
S365A 3.4  ± 1.3  1.9  ± 0.6  0.56  ± 0.14  
S365G 5.2  ± 2.7  0.76  ± 0.35  0.15  ± 0.07  
S368A 3.0  ± 1.0  6.0  ± 1.7  2.0  ± 0.4  
S368G 3.4  ± 0.7  2.8  ± 0.5  0.83  ± 0.05  
K370A 0.86  ± 0.29  0.075  ± 0.014  0.086  ± 0.013  
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Table 3  
Data collection and refinement statistics 
Space group C2 
Unit cell parameters (Å, deg) 
a = 91.84, b = 50.96, c = 85.82 
β = 115.73 
Data collection  
 Wavelength (Å) 1.0000 
 Resolution limit (last shell)a (Å) 50-1.35 (1.40-1.35)a 
 Measured reflections 368,700 
 Unique reflections 78,862 (7,783) 
 Redundancy 4.7 (3.9) 
 Completeness (%) 99.9 (100) 
 I/σ (I) 32.5 (3.72) 
 Rmerge (%) 0.091 (0.37) 
 Wilson B-factor (Å2) 13.5 
Refinement  
 Resolution limit (Å) 45.64-1.35 (1.38-1.35) 
 Used reflections 78,821 (5,304) 
 Completeness (%) 99.7 (97.4) 
 R-factor (%) 13.2 (14.9) 
 Rfree (%) 16.0 (21.4) 
Final model  
 No. of molecules 
 /asymmetric unit 1 
 No. of nonhydrogen atoms  
 Protein 3,244 
 HEPES 15 
 H2O 422 
 Average isotropic B-factor (Å2)  
 Protein 16.7 
 HEPES 30.1 
 H2O 27.5 
  
 r.m.s.d. from ideal  
  Bond length (Å) 0.009 
  Bond angle (deg) 1.226 
 Ramachandran plot (%)  
  Favored region 97.8 
  Allowed region 2.2 
  Outlier region 0 
aData in highest resolution shells are given in parentheses.  
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Figure 1  
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Figure 5 
 
 
